Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

27.05.2016

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building.
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

By BSE Listing

National Stock Exchange of India Ltd., Department of Corporate Services Exchange Plaza, 5th Floor, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Code: CAPLIPOINT.

By NEAPS

Dear Sirs,

SUB: PRESS RELEASE

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find the enclosed copy of Communication being released to the press with respect to the Financial Results.

Thanking You,

Yours Faithfully,
For Caplin Point Laboratories Limited

Company Secretary Enclosures: as above

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

PRESS RELEASE

Topline in 2010 becomes bottom line in 2016

Results - Q3 FY 16 and FY 2016

Chennai, May 27, 2016: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) today reported its financial results for the Quarter (Q3 FY 16) and 9months financial year ended March 31, 2016.

Key Financial & Performance Highlights - Consolidated

INR Lacs

Details	Q3 FY 16	Q3 FY 15	Growth %	FY 16 (9M)	FY 15	Growth (Annualised)
Gross Revenue	8,191	6,362	29%	23872	25177	26%
EBITDA	2210	1607	38%	6764	6200	45%
EBITDA %	27%	25%		28%	25%	
PAT	1558	1061	47%	4577	4104	49%
PAT %	19%	17%		19%	16%	

Key Financial & Performance Highlights - Standalone

Details	Q3 FY 16	Q3 FY 15	Growth %	FY 16 (9M)	FY 15	Growth (Annualised)
Gross Revenue	7,864	6,092	29%	23129	24023	28%
EBITDA	2120	1496	42%	6579	5930	48%
EBITDA %	27%	25%		28%	25%	
PAT	1515	1060	43%	4,533	4094	48%
PAT %	19%	17%		20%	17%	

The company is glad to announce a unique milestone - what was the topline in 2010 has now become the bottom line in 2016 (Apr – Mar 2016) on a consolidated basis. EBITDA, PBT and PAT for the nine months ending Mar 16 has strengthened considerably in absolute terms than the last fiscal year July 14 – June 15, with growth on annualised basis at 45%, 50% and 49% respectively.

Uniff No: 85/3, Sylhyleny Village, Mannadipet Commune, Puducherry - 605 502. Ph.: +91 413 2674046 / 4047

Unit 1. No. 19, Chrimopuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District. Pincode - 601 201. Ph.: +91 44 27900901 Unit 111. BHASRA No. 435, Village Suraj Majra, N.H. No. 21, Baddi, Teh. Nalagarh, District Solan, Himachal Pradesh — 173205. Ph.: +91 1795 245512

Unit IV: Survey No.: 895 & 897, Guruvarajakan'digai, Sirupuzhalpettai (Post.), Gummidipoondi. Taluk, Thiruvallur District, Pincode - 601 201.

Ph.: +9197884 59333/69333

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

Company has added another 250 new product registrations in the 9 month period, taking the total tally to over 1800 active registrations as on date. Approval for another 300 products are expected in the next 3-4 Quarters. Softgel and Penem sections which were added last year has shown satisfactory results and are expected to boost sales when further new registrations are received.

As part of its expansion strategy going forward, the Company is in the process of setting up subsidiaries in Colombia, Ecuador and Hong Kong in the next few months.

Regulated Markets

Company has already received Brazil's ANVISA GMP approval for its injectable plant, known to be one of the most stringest inspections. Product filings are on the way and approvals are expected in 2017. Company is at advanced stages of filing its first ANDA, which will trigger the US FDA inspection in the near future. Company is in the process of developing 5 ANDA's for own filing and another 4 ANDA's through partners.

R&D

Total R & D spend has seen major increase from INR 775 lacs during FY 14-15 (12 months) to INR 865 lacs during FY16 (9 months). Growth on an annualised basis accounted for 49 %. This constitutes to around 19% of PAT, spent on R&D. Company expects this figure to increase considerably in the next 12-24 months due to ramping up of R&D manpower and machinery, as more ANDA filings are planned. The company has also increased the number of scientists in R&D from 68 to 97, around 43% higher compared to the previous year.

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.

Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company currently holds over 1800 product licenses across Latin America and Africa, with another 300 in the pipeline. The company is entering into the regulated markets for injectables, having already been approved by EU and Brazil and expecting US FDA approval in the near future.



Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

